Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Different Thienopyridine Loading Strategies to Get the Fastest Effect

Original Title: Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention. The Excelsior LOAD Trial. Reference: Willibald Hochholzer et al. J Am Coll Cardiol Intv. 2016, online before print.

 

This study assesses how to provide a more rapid antiaggregant effect. It compares the effect of a prasugrel load vs. a 600 mg clopidogrel load, seeing that an effective antiplatelet inhibition at PCI start reduces the risk of ischemic complications.

Clopidogrel administration immediately before PCI provides effective antiaggregation only 2 hours later. Prasugrel has, in theory, the potential to shorten this period.

This study randomly assigned 300 P2Y12 receptor blocker–naive patients undergoing an elective PCI to loading with clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg immediately before the PCI. Platelet function was assessed serially by impedance aggregometry. The primary endpoint was the proportion of patients with high platelet reactivity defined as ≥468 aggregation units per minute, at 60 min after loading.

At 60 min, 33% of patients assigned to prasugrel 60 mg, 37% of patients assigned to prasugrel 30 mg, and 55% of those assigned to clopidogrel 600 mg had high platelet reactivity (p < 0.001). As from 30 min, prasugrel 60 mg patients achieved significantly lower platelet reactivity than clopidogrel patients. Platelet reactivity at 60 min after prasugrel was not significantly different from that at 120 min after clopidogrel. Prasugrel 30 mg had an intermediate effect. The 30-day incidence of bleeding events was similar in the 3 groups.

Conclusion
As from 30 min, prasugrel 60 mg achieved a stronger platelet inhibition than clopidogrel loading. Compared with clopidogrel, prasugrel 60 mg was associated with a twice as fast onset of platelet inhibition.

Editorial Comment
Patients in this study were stable and PCI was programmed and elective; this is why the slowest onset of platelet inhibition with clopidogrel could be solved by a 600 mg load 2 hours prior procedure. Prasugrel was superior in the short term; however, there is no evidence to support the safety and efficacy of prasugrel followed by clopidogrel maintenance therapy, in this study.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...